디자인 테라퓨틱스(DSGN)는 NASDAQ에 상장된 Healthcare · Biotechnology 기업입니다. 현재가 $12.53 (-2.19%), 시가총액 $0.83B, 52주 최저~최고 $3.21 ~ $15.79.
Design Therapeutics, Inc. a clinical-stage biopharmaceutical company, research, designs, develops, and commercializes small molecule therapeutic drugs for the treatment of genetic diseases in the United States. The company utilizes its GeneTAC platform to design and develop therapeutic candidates for inherited diseases caused by nucleotide repeat expansion. Its lead product candidates for potentially disease-modifying treatment comprises Friedreich Ataxia, a monogenic, autosomal recessive, progressive multi-system disease that affects organ systems dependent on mitochondrial function that brings to neurological, cardiac, and metabolic dysfunction; Myotonic Dystrophy Type-1, a dominantly-inhe
디자인 테라퓨틱스의 재무제표, 목표주가, 기관투자자(13F) 보유 현황, 관련 뉴스는 BlackAll Trade에서 실시간으로 확인할 수 있습니다.
디자인 테라퓨틱스의 현재 주가는 $12.53 (-2.19%)입니다. BlackAll Trade에서 실시간 시세와 차트를 확인할 수 있습니다.
디자인 테라퓨틱스의 시가총액은 약 $0.83B입니다.
Design Therapeutics, Inc. a clinical-stage biopharmaceutical company, research, designs, develops, and commercializes small molecule therapeutic drugs for the treatment of genetic diseases in the Unit